Achillion Announces Resignation of Chief Medical Officer
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced the resignation of Elizabeth A. Olek, D.O., Senior Vice President of Clinical Development and Chief Medical Officer, effective June 18, 2012. Milind Deshpande, Ph.D., President of Research and Development and Chief Scientific Officer, will assume responsibility for the oversight of ongoing and planned clinical trials evaluating Achillion's portfolio of compounds for the treatment of hepatitis C (HCV).
"Achillion's clinical programs have matured extensively during Liz's tenure, and during that time, our robust pipeline of HCV compounds, focused on pan-genotypic protease inhibitors and NS5A inhibitors, has advanced from discovery into early and mid-stage clinical trials. We thank Liz for her significant contributions to that development progress and wish her the best of luck in her future endeavors," said Michael D. Kishbauch, President and Chief Executive Officer of Achillion.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.